|
|
|
|
|
|
|
The Rare Disease Patients Experience
|
|
When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
European Commission Approves BYANNLIŽ (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults
BYANNLIŽ (6-monthly paliperidone palmitate; PP6M) is the first long-acting
injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study,
which showed that 92.5 percent of patients treated with PP6M were relapse-free at
the end of the 12-month double-blind phase1.
More info >> |
|
 |
White Papers |
 |
|
The Rare Disease Patients Experience
When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >> |
|
|
|
